AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.
KD: 0.5 nM (C3).
体内研究 (In Vivo)
AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis. AMY-101 can induce a long-lasting anti-inflammatory effect. AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction. AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
0.1 mg/site; 50 μL of 2 mg/mL solution.
Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Does not cause irritation in healthy gingiva.
UUO and sham-operated mice.
Subcutaneous injection every 12 h, daily, 7 or 14 days.
1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.